Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer

被引:0
|
作者
Shen, Qiang [1 ]
Murakami, Kiichi [1 ]
Sotov, Valentin [1 ]
Butler, Marcus [1 ,2 ,3 ]
Ohashi, Pamela S. [1 ,4 ,5 ]
Reedijk, Michael [1 ,5 ,6 ]
机构
[1] Univ Hlth Network, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[3] Univ Toronto, Dept Med, Div Med Oncol, Toronto, ON, Canada
[4] Univ Toronto, Dept Immunol, Med Sci Bldg,1 Kings Coll Circle,Room 7205, Toronto, ON M5S 1A8, Canada
[5] Univ Toronto, MaRS Ctr, Dept Med Biophys, Toronto Med Discovery Tower,101 Coll St,Room 15-70, Toronto, ON M5G 2M9, Canada
[6] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Surg Oncol, 610 Univ Ave,Suite 8-411, Toronto, ON M5G 2M9, Canada
来源
SCIENCE ADVANCES | 2024年 / 10卷 / 44期
基金
加拿大健康研究院;
关键词
TUMOR-ASSOCIATED MACROPHAGES; SIGNALING PATHWAY; CELLS; INFLAMMATION; NIVOLUMAB; THERAPY; INVASIVENESS; EXPRESSION; MICROENVIRONMENT; PEMBROLIZUMAB;
D O I
10.1126/sciadv.ado8275
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Aberrant Notch, which is a defining feature of triple-negative breast cancer (TNBC) cells, regulates intercellular communication in the tumor immune microenvironment (TIME). This includes tumor-associated macrophage (TAM) recruitment through Notch-dependent cytokine secretion, contributing to an immunosuppressive TIME. Despite the low response rate of TNBC to immune checkpoint blockade (ICB), here, we report that inhibition of Notch-driven cytokine-mediated programs reduces TAMs and induces responsiveness to sequentially delivered ICB. This is characterized by the emergence of GrB+ cytotoxic T lymphocytes (CTLs) in the primary tumor. A more impressive effect of sequential treatment is observed in the lung where TAM depletion and increased CTLs are accompanied by near-complete abolition of metastases. This is due to (i) therapeutic reduction in Notch-dependent, prometastatic circulating factors released by the primary tumor, and (ii) elevated PD ligand 1 (PD-L1) in lung metastases, rendering them profoundly sensitive to ICB. These findings highlight the potential of combination cytokine inhibition and ICB as an immunotherapeutic strategy in TNBC.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
    Isaacs, James
    Anders, Carey
    McArthur, Heather
    Force, Jeremy
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (05)
  • [2] Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer
    Michel, Laura L.
    von Au, Alexandra
    Mavratzas, Athanasios
    Smetanay, Katharina
    Schuetz, Florian
    Schneeweiss, Andreas
    TARGETED ONCOLOGY, 2020, 15 (04) : 415 - 428
  • [3] Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
    James Isaacs
    Carey Anders
    Heather McArthur
    Jeremy Force
    Current Treatment Options in Oncology, 2021, 22
  • [4] Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer
    Sceneay, Jaclyn
    Goreczny, Gregory J.
    Wilson, Kristin
    Morrow, Sara
    DeCristo, Molly J.
    Ubellacker, Jessalyn M.
    Qin, Yuanbo
    Laszewski, Tyler
    Stover, Daniel G.
    Barrera, Victor
    Hutchinson, John N.
    Freedman, Rachel A.
    Mittendorf, Elizabeth A.
    McAllister, Sandra S.
    CANCER DISCOVERY, 2019, 9 (09) : 1208 - 1227
  • [5] Immune checkpoint inhibition in early-stage triple-negative breast cancer
    Varma, Revati
    Wright, Matthew
    Abraham, Jame
    Kruse, Megan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (11) : 1225 - 1238
  • [6] Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model
    Maia, A. R. R.
    de Man, J.
    Boon, U.
    Janssen, A.
    Song, J. -Y.
    Omerzu, M.
    Sterrenburg, J. G.
    Prinsen, M. B. W.
    Willemsen-Seegers, N.
    de Roos, J. A. D. M.
    van Doornmalen, A. M.
    Uitdehaag, J. C. M.
    Kops, G. J. P. L.
    Jonkers, J.
    Buijsman, R. C.
    Zaman, G. J. R.
    Medema, R. H.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2180 - 2192
  • [7] Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer
    Quintana, A.
    Saini, K. S.
    Vidal, L.
    Peg, V.
    Slebe, F.
    Loibl, S.
    Curigliano, G.
    Schmid, P.
    Cortes, J.
    ESMO OPEN, 2024, 9 (10)
  • [8] The role of immune checkpoint inhibition in triple negative breast cancer
    Tarekegn, Kidist
    Keskinkilic, Merve
    Kristoff, Tyler J.
    Evans, Sean T.
    Kalinsky, Kevin
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (10) : 1095 - 1106
  • [9] Lidocaine enhances the efficacy of palbociclib in triple-negative breast cancer
    Han, Beom Seok
    Jung, Kyung Hee
    Lee, Ji Eun
    Yoon, Young-Chan
    Ko, Soyeon
    Park, Min Seok
    Lee, Yun Ji
    Kim, Sang Eun
    Cho, Ye Jin
    Lee, Pureunchowon
    Lim, Joo Han
    Jang, Eunsoo
    Kim, Hyunzu
    Hong, Soon-Sun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (07): : 3083 - 3098
  • [10] Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer
    Lu, Guowen
    Qiu, Yier
    Su, Xiaobao
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 157